Business Context and Reporting Period
This Form 8-K was filed by Quince Therapeutics, Inc. (QNCX) on December 4, 2023. The Company is a Delaware corporation with principal executive offices in South San Francisco, California, and its common stock is listed on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
On December 4, 2023, the Company received written notice from Nasdaq stating it no longer complies with the minimum bid price requirement for continued listing. Specifically, the closing bid price of the Common Stock remained below $1.00 per share for 30 consecutive trading days, violating Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-calendar-day compliance period to regain compliance, ending on June 3, 2024.
- Requirements to Cure: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive trading days prior to the deadline.
- Alternative Options: If compliance is not met by June 3, 2024, the Company may be eligible for an additional 180-day period if it elects to transfer to The Nasdaq Capital Market, subject to meeting other listing standards such as market value of publicly held shares.
- Risks: There is no assurance the Company will regain compliance or that Nasdaq will grant further extensions. Failure to comply within the allowed periods will result in the delisting of the Common Stock.
- Management Action: The Company intends to monitor the stock price and consider available options to resolve the noncompliance.
Investor Verification Checklist
- Verify the current closing bid price of QNCX common stock to assess progress toward the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other corporate actions intended to increase the share price.
- Check for future filings indicating an election to transfer to The Nasdaq Capital Market if the initial compliance period expires without resolution.
- Review the Company's most recent 10-K or 10-Q for financial liquidity data, as this 8-K does not contain financial statements.